Long-term debt · 2020–2025
Starling Oncology long-term debt
$77.4M−16.9% · FY2025
Starling Oncology (STLN) reported $77.4M in long-term debt for fiscal 2025, −16.9% year on year.
Long-term debt — Long-term debt is borrowing due more than a year out. A large figure is normal for capital-intensive businesses and says nothing on its own about financial health.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2020–2025 compound annual growth +63.8%
Long-term debt at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Starling Oncology long-term debt |url=https://companiesranked.com/en/company/starling-oncology/long-term-debt |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Starling Oncology long-term debt. CompaniesRanked. https://companiesranked.com/en/company/starling-oncology/long-term-debtBibTeX
@misc{companiesranked-en-company-starling-oncology-long-term-debt-2026,
author = {{CompaniesRanked}},
title = {{Starling Oncology long-term debt}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/starling-oncology/long-term-debt}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001799191-26-000017 · August 6, 2026
{{cite web |title=Starling Oncology long-term debt — 10-Q (0001799191-26-000017) |url=https://www.sec.gov/Archives/edgar/data/1799191/000179919126000017/toi-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.